Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Cindy L. Schwartz MD, MPH
Chief, Professor
Department of Pediatrics
Division of Hematology and Oncology - Pediatrics

OFFICE ADDRESS:
MACC Fund Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:
1975 BS in Chemistry, Yale College, New Haven, CT
1975 - Present BS in Chemistry, Yale College, New Haven, CT
1977 - Present (transferred to Brown), UMDNJ Rutgers Medical School, Piscataway, NJ
1977 (transferred to Brown), UMDNJ Rutgers Medical School, Piscataway, NJ
1979 MD, Brown University Program in Medicine, Providence, RI
1979 - Present MD, Brown University Program in Medicine, Providence, RI
2011 - Present MPH, Harvard School of Public Health, Boston, MA
2011 MPH, Harvard School of Public Health, Boston, MA

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
1979 - 1982 Resident, Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD
1979 - 1982 Resident, Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD
1982 - 1985 Fellow, Pediatrics, Hematology/Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
1982 - 1985 Fellow, Pediatrics, Hematology/Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
2011 - Present Public Leadership, Center for Public Leadership, Harvard Kennedy School, Cambridge, MA
2011 Public Leadership, Center for Public Leadership, Harvard Kennedy School, Cambridge, MA
2015 - 2016 Leadership, Faculty Leadership Academy, MDACC, Houston, TX
2015 - 2016 Leadership, Faculty Leadership Academy, MDACC, Houston, TX

MILITARY SERVICE:
N/A

FACULTY APPOINTMENTS:
07/1983 - 11/1985 Assistant in Oncology, Department of Oncology and Pediatrics, Division of Pediatrics Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
11/1985 - 06/1992 Assistant Professor, Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Rochester, Rochester, NY
07/1992 - 04/1994 Associate Professor, Department of Pediatrics, Division of Pediatrics Oncology, University of Rochester, Rochester, NY
04/1994 - 08/2005 Associate Professor, Department of Oncology and Pediatrics, Division of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
08/2005 - 09/2013 Professor, Department of Pediatrics, Division of Pediatrics Hematology/Oncology, Brown University, Providence, RI
09/2013 - 05/2017 Professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
05/2017 - Present Professor, Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:
12/1988 - 04/1994 Medical Director, Pediatric Hematology/Oncology, Long Term Survivors Clinic, University of Rochester Medical Center/Strong Memorial Hospital, Rochester, NY
01/1990 - 04/1994 Clinical Director of Pediatric Hematology/Oncology, Pediatric Hematology/Oncology, University of Rochester Medical Center, Strong Memorial Hospital, Rochester, NY
04/1993 - 04/1994 Acting Division Director, University of Rochester, Rochester, NY
04/1994 - 09/2003 Associate Director of Clinical Programs in Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
04/1994 - 08/2005 Director, Long-Term Program in Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
09/2003 - 08/2005 Associate Director of Clinical Research, Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
08/2005 - 09/2013 Director, Division of Pediatric Hematology/Oncology, Brown University, Providence, RI
01/2006 - 09/2013 Director, CHAMPS Survivorship Program, Providence, RI
08/2006 - 09/2013 Endowed Alan G. Hassenfeld Professor of Pediatric Oncology, Warren Alpert School of Medicine, Department of Pediatrics, Brown University, Providence, RI
2007 - 2013 Member, Consortium for New England Childhood Cancer Services, Providence, RI
09/2013 - 05/2017 Deputy Division Head for Clinical and Translational Research, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
2013 - 05/2017 Director, Pediatric Phase I, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
2013 - 05/2017 Director of Clinical and Translational Research, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
01/2015 - 05/2017 Section Chief for Non-neural solid tumors, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
02/2015 - 12/2016 Department Chair ad interim, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
02/2015 - 12/2016 Division of Pediatrics, The University of Texas MD Anderson Cancer Center, TX, Division Head ad interim, Houston
06/2015 - 05/2017 Endowed Edgar Lewis Curtis, Savilla Elizabeth Curtis, and Eleanor Lewis Curtis Distinguished Professorship in Pediatric Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX
2016 - 05/2017 Director, Adolescent and Young Adult Oncology Program Development, The University of Texas MD Anderson Cancer Center, Houston, TX
05/2017 - Present Rebecca Jean Slye Chair of Oncology, Children's Hospital of Wisconsin, Milwaukee, WI
05/2017 - Present Section Chief, Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
05/2017 - Present Medical Director of Hematology/Oncology/BMT, Children's Hospital of Wisconsin, Milwaukee, WI

RESEARCH ADMINISTRATIVE APPOINTMENTS:
1992 - 1994 Principal Investigator, Pediatric Oncology Group, University of Rochester, Rochester, RI
1994 - 2000 Principal Investigator, Pediatric Oncology Group, Johns Hopkins University, Baltimore, MD
2001 - 2005 Principal Investigator (Brown University), Children's Oncology Group, Arcadia, CA
2001 - 2005 Principal Investigator (Johns Hopkins University), Children's Oncology Group, Arcadia, CA
2005 - 2013 Principal Investigator (RIH/Brown), Children's Oncology Group (COG), St. Louis, MO
2007 - 2013 Principal Investigator (Brown University), Dana Farber ALL Consortium, Providence, RI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
American Board of Pediatrics
1985
None
American Board of Pediatrics-Hematology/Oncology
1994
None
 
Licensure
Number Issue DateExpiration
Medical License MD
D28219
08/1982
1987
Medical License NY
165175-1
01/1986
12/1994
Temporary Medical License MA
412T
1993
1995
Medical License MD
D28219
1994
09/2005
Medical License MA
81701
1995
2000
Medical License RI
MD11815
05/2005
06/2014
Temporary Medical License TX
44360
09/2013
09/2014
Medical License TX
01296
08/2014
2017
Medical License WI
67411 - 20
05/18/2017
None
 

AWARDS AND HONORS:
1971 National Merit Finalist
1979 - Present Sigma XI, Medical Science Society
1983 - 1984 Clinical Fellowship, American Cancer Society
1999 Recognition Award, Pediatric Oncology Group
2001 - 2016 America's Top Doctors
2001 - 2011 Recognition Award, Hodgkin Lymphoma Chair
2005 - 2016 America's Top Doctors For Cancer
2010 Women Making Strides Award, Ronald McDonald House of Providence, RI
2010 Lifespan Executive Mentorship Program
2010 Recognition Award, Tomorrow Fund
2011 Best Clinical Trial Finalist, International Society of Paediatric Oncology (SIOP)
2011 Recognition Award, Children's Oncology Group (COG)
2016 - Present Top 211 Docs in Houston, Houston Chronicle's MedCity Magazine

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
1986 - 1988 Pediatric Oncology Group Children's Study Cancer Group (Member)
1988 - Present American Society of Pediatric Hematology/Oncology (Member)
1989 - Present American Socieity of Clinical Oncology (Member)
1989 - 2000 Pediatric Oncology Group Hodgkin's Disease Committee (Member)
1990 - 1994 American Cancer Society: Upstate New York Pediatric Oncology Group (Member)
1992 - 1994 Pediatric Oncology Group: Pricipal Investigator - University of Rochester
1992 - 1999 Women in Cancer Research (Member)
1994 - 2000 Pediatric Oncology Group Sarcoma Intergroup/Transition Committee (Member)
1994 - 2000 Pediatric Oncology Group Sarcoma Committee (Member)
1995 - 2001 National Cancer Center Network Pediatric Committee (Member)
1998 - 2003 Children's Cancer Foundation Medical Advisory Committee (Member)
1998 - Present Israel Children's Cancer Foundation Medical Advisory Board (Member)
1999 - 2001 American Socieity of Clinical Oncology Publications Committee (Member)
1999 - 2001 National Cancer Center Network Osteosarcoma Subcommittee (Member)
1999 - 2002 American Society of Pediatric Hematology/Oncology Program Committee (Member)
1999 - 2000 Pediatric Oncology Group Hodgkin's Transition Committee (Co-Chair)
1999 - 2000 Pediatric Oncology Group Hodgkin's Committee (Chair)
2000 - Present Children's Oncology Group (Member)
2001 - 2006 Children's Oncology Group Developmental Therapeutic Committee (Member)
2001 - Present Children's Oncology Group Bone Tumor Committee (Steering Committee)
2001 - Present Children's Oncology Group Hodgkin Committee (Steering Committee)
2001 - 2013 Children's Oncology Group Voting Body (Member)
2001 - 2003 Children's Oncology Group Steering Committee (Member)
2001 - 2011 Children's Oncology Group Scientific Chairs Committee (Member)
2001 - 2011 Children's Oncology Group Hodgkin Disease Committee (Chair)
2001 - 2006 Children's Oncology Group Osteosarcoma Biology Committee (Member)
2001 - 2005 Children's Oncology Group (PI, Johns Hopkins University)
2002 - 2010 Children's Oncology Group Adolescent/Young Adult Steering Committee (Member)
2003 - Present American Society of Hematology (Member)
2003 - 2011 American Socieity of Clinical Oncology Patients Living with Cancer Advisory Board (Hodgkin's disease) (Member)
2003 - 2005 Children's Oncology Group Survivorship Transition Sub-Committee (Member)
2005 - 2009 American Socieity of Clinical Oncology CME Committee (Member)
2005 - 2007 American Socieity of Clinical Oncology Expert Panel on Long-Term Medical Care for Adult Cancer Survivors (Member)
2005 - 2013 Children's Oncology Group (PI, RIH/Brown University)
2006 - 2013 Tomorrow Fund Executive Board and Program Education Committee (Member)
2007 - Present American Pediatric Society (Member)
2008 - 2013 Dana Farber ALL Consrtium (Member)
2009 - 2012 American Society of Pediatric Hematology/Oncology Nominating Committee (Member)
2010 - 2013 Children's Oncology Group Executive Committee (Member)
2011 - 2012 American Society of Pediatric Hematology/Oncology Nominating Committee (Chair)
2013 - Present Hematology Oncology Discipline Steering Committee (Member)
2014 - Present Children's Oncology Group Institutional Performance Monitoring Committee (Member)
2015 - Present National Cancer Center Network: Adolescent Young AdultCommittee (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorship
2013 - Present Journal of Pediatric Hematology Oncology
Editorial Board
1997 - 1999 Journal of Clinical Oncology
2003 - 2006 Journal of Clinical Oncology
2004 - 2008 Pediatric Blood and Cancer
2015 - 2017 Cardio-Oncology
Journal Review
1989 - Present Cancer
1990 - Present American Journal of Pediatric Hematology/Oncology
1990 - Present Journal of Clinical Oncology
1991 - 1995 International Journal of Radiation Oncology and Biological Physics
1996 - Present New England Journal of Medicine
1997 - Present Archives of Pediatric & Adolescent Medicine
1998 - Present Journal National Cancer Institute
2000 Internal Journal of Pediatric Hematology/Oncology
2002 - Present Mayo Clinic Procedures
2003 Journal of American Medical Association (JAMA)
2004 - Present Pediatric Blood and Cancer
2012 Supportive Care in Cancer
2014 Annals of Oncology

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
07/2017 - Present Member, CRI Research Unit Leaders Group
2017 - Present Committee Member, MCW Cancer Center Clinical Research Executive Committee, Medical College of Wisconsin
2017 - Present Committee Member, MCW Cancer Center Executive Committee, Medical College of Wisconsin

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
1988 - 1990 Member, Dept. of Pediatrics Education Committee, University of Rochester
1988 - 1994 Member, Dept. of Pediatrics Intern Selection Committee, University of Rochester
1989 - 1993 Member, Dept. of Pediatrics Quality Assurance Committee, University of Rochester
1989 - 1994 Member, Cancer Center Protocol Review Board, University of Rochester
1993 - 1994 Member, Dept. of Pediatrics Division Chiefs Committee, University of Rochester
1994 - 1998 Member, Center Clinical Chiefs Committee, Johns Hopkins Oncology
1994 - 1996 Member, Center Medical Services Committee, Johns Hopkins Oncology
1994 - 2005 Member, Center Clinical Research Committee, Johns Hopkins Oncology
1994 - 1995 Member, Center Quality Assurance Committee, Johns Hopkins Oncology
1995 - 2001 Member, Pediatrics at Home Board of Directors, Johns Hopkins Hospital
1995 - 1997 Member, Oncology Center Greenspring Subcommittee, Johns Hopkins University
1995 - 2005 Member, Pediatric Residency Review Committee, Johns Hopkins University
1995 - 1996 Member, Pediatrics Clinical Leaders Committee, Johns Hopkins University
1995 - 1998 Member, Oncology Center Clinical Research Advisory Committee, Johns Hopkins University
1995 - 1997 Member, Pediatric Oncology Task Force, Johns Hopkins University
1996 - 1997 Chair, Oncology Center Clinical Investigator Subcommittee, Johns Hopkins University
1996 - 2005 Coordinator/Member, Pediatric Oncology Clinical Research Committee, Johns Hopkins University
1996 - 1998 Member, Pediatric Oncology Tumor Board Coordinator, Johns Hopkins University
1996 - 2005 Member, Admissions Committee, Johns Hopkins University School of Medicine
1996 - 2001 Member, Pediatric Hospice Medical Advisory Committee, Johns Hopkins Hospital
1996 - 2005 Member, Cancer Committee, Johns Hopkins Hospital
1999 - 2001 Chair, Hodgkin Disease Committee, Pediatric Oncology Group (POG), St. Louis, MO
1999 - 2000 Member, Sub-committee Internal Relations of Clinical Practice Association, Johns Hopkins Hospital
1999 - 2005 Member, Oncology Center Clinical Research Executive Committee, Johns Hopkins University
1999 - 2001 Member, Children's Center Operations Committee, Johns Hopkins Hospital
1999 - 2005 Member, Oncology Center Clinical Practice Committee, Johns Hopkins University
2000 - Present Member, Steering Committee, COG Bone Tumor, Children's Oncology Group (COG), Arcadia, CA
2001 - 2003 Member, Steering Committee, COG Voting Body, Children's Oncology Group (COG), Arcadia, CA
2001 - 2011 Member, Scientific Chairs Committee, Children's Oncology Group (COG), Arcadia, CA
2001 - Present Member, Steering Committee, COG Hodgkin Committee, Children's Oncology Group, Arcadia, CA
2001 - 2011 Chair, Hodgkin Lymphoma Committee, Children's Oncology Group (COG), Arcadia, CA
2002 - 2011 Member, Pediatric Cancer Treatment Advisory Board, Washington DC, National Cancer Institute, Physician Data Query
2002 - 2005 Member, Oncology Center Executive Clinical Trials Unit, Johns Hopkins University
2002 - Present Chair, Data Safety Monitoring Board, NANT- Novel Approaches to Neuroblastoma Therapy, Los Angeles, CA
2003 - 2005 Member, Pediatric Oncology Core Clinical Care Committee, Johns Hopkins University
2003 - 2005 Member, Oncology Center Physician Assistant/ Nurse Practitioner Council, Johns Hopkins University
06/2004 - 06/2011 Member, Scientific Advisory Board, Childhood Cancer Survivor Study (CCSS), Memphis, TN
2005 - 2013 Member, Cancer Committee, Rhode Island Hospital
2006 - 2008 Member, Data Safety Monitoring Board, Columbia University/Babies' Hospital Pediatric Hematology/Oncology/BMT, New York, NY
2006 - 2013 Member, Chemotherapy Safety Initiative Group, Rhode Island Hospital
2006 - 2007 Member, Search Committee for Pediatric Hematologist/Oncologist, Warren Alpert Medical School of Brown University
2006 - 2013 Member, BMT/CON Group, Rhode Island Hospital
2006 - 2013 Member, Oncology Sub-Council, Rhode Island Hospital
2007 - 2013 Member, Brown University Oncology Group (BRUOG), Warren Alpert Medical School of Brown University
2007 - 2013 Member, Oncology Council, Rhode Island Hospital
2008 - 2011 Member, Committee on Medical Faculty Appointments, Warren Alpert Medical School of Brown University
2008 - 2013 Founding Member, Steering Committee, Consortium for New England Childhood Cancer Survivors, Providence, RI
2008 - 2013 Chair, Research Committee, Consortium for New England Childhood Cancer Survivors, Providence, RI
2008 - 2011 Chair, Search Committee for Pediatric Pulmonologist, Warren Alpert Medical School of Brown University
2009 - 2013 Expert Panel on Radiation Oncology - Hodgkin Lymphoma, American College of Radiology Appropriateness Criteria Committee, Radiation Oncology Panel, Reston, VA
2009 - 2013 Member, Pediatric Promotion Committee, Warren Alpert Medical School of Brown University
2010 - 2011 Member, Search Committee for Chief of Pathology, RIH, Warren Alpert Medical School of Brown University
2010 - 2013 Member, COG Executive Committee, Children's Oncology Group (COG), Arcadia, CA
2011 - 2013 Member, Department of Pediatrics Research Task Force, Rhode Island Hospital
2012 - 2013 Member, Search Committee for Chair of Dermatology, Warren Alpert Medical School of Brown University
2013 - 2017 Member, Executive Leadership Committee, MDACC Children's Cancer Hospital
2013 - 2014 Member, Pediatrics Women's Faculty Committee, MDACC
2013 - Present Member, Steering Committee, Hematology Oncology Discipline, Children's Oncology Group (COG), Arcadia, CA
2013 - Present Member, Joint Sarcoma Committee, MDACC/TCH
2013 Member, Search Committee for Pediatric Hematologist/Oncologist, Warren Alpert Medical School of Brown University
2013 - 2014 Member, Pediatrics Clinical Research Operations, MDACC
2014 Member, Clinical Research Committee #3, MDACC
2014 - 2017 Member, Vice Provost Advisory Council (VPAC)
2014 - 2017 Member, Rare Tumor Working Group, MDACC
2014 - 2017 Member, Rare Tumor Working Group, MDACC
2015 - Present Director, Adolescent and Young Adult Program Planning Group
2015 - 2016 Member, Division Head Committee, MDACC
2015 - 2016 Member, Executive Clinical Operations Team
2015 - 2016 Member, Medical Specialties Work Group, MDACC/UTMB
2015 - 2017 Member, Model of Care Workgroup
2015 - 2016 Member, PRS Executive Council
2015 - 2017 Chair, Pediatric POTIS Board, MDACC
2015 - Present Member, Data Safety Monitoring Board, St. Jude Children's Hospital, Memphis, TN
2015 - 2017 Chair, Pediatric Advisory Committee for Clinical Trials, MDACC
2015 - Present Director, Adolescent and Young Adult Program Planning Group
2015 - 2016 Member, Shared Governance Committee, MDACC
2015 - 2016 Member, PRS Executive Council
2015 - 2017 Member, Clinical Department Chairs, MDACC
2015 - 2017 Member, Model of Care Workgroup
2015 - Present Member, Neuroblastoma Committee
2016 - Present Member, Clinical Research Advisory Committee
2016 - Present Member, Clinical Research Advisory Committee
2016 - 2017 Member, Research Informatics Subcommittee, MDACC
10/2018 Planning Committee Member, ASPHO/COG CME Symposium, American Society of Pediatric Hematology/Oncology (ASHPO)

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Dexrazoxane Follow-up Study: Revisiting POG 9404/9425/9426
Source:
St. Baldrick's Consortium Research Grant
Role:
Co-Investigator
Dates:
2012 - 2017
Direct Funds:
$50,000 ($10,000/year)
 
Title:
Phase I Dose Escalation of Monthly Intravenous Ra-223 dichloride in Osteosarcoma, 2013-00037360JW
Source:
Bayer Healthcare AG
Role:
Collaborator (MDACC)
PI:
Subbiah
Dates:
2013 - Present
 
Title:
Immunomodulatory effects of nutritional intervention in malnourished pediatric oncology patients
Source:
Pediatric Clinical Innovator Award
Role:
Co-Investigator
PI:
Fogelsong J
 
Pending
Peer Review
Title:
Pre-surgical Supervised Exercise for Bone Cancer Patients
Role:
Co-Principal Investigator
PI:
V. Lewis and CL. Schwartz
Dates:
2016 - Present
 
Title:
R01 CA211996-01 Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Source:
MDACC
Role:
Co-Investigator
PI:
E. Chow
Dates:
2017 - 2021
Direct Funds:
$94,770 (Informed that this will be funded)
 
Prior
Peer Review
Title:
The Biology and Treatment of Human Leukemia and Lymphoma, CA-34183-11
Source:
NIH/NCI
Role:
Principal Investigator (University of Rochester 1993-1994)
PI:
Stephen Sallan, MD (DFCI)
Dates:
08/01/1983 - 12/31/1994
Direct Funds:
$147,123
 
Title:
A case control study of Hodgkin's disease in childhood, POG8829
Source:
NCI/POG
Role:
Collaborator
PI:
S. Grufferman
Dates:
1988 - 2003
 
Title:
Late Effects of Treatment of Hodgkin's Disease - A Pediatric Oncology Group Non-Therapeutic Study, POG8828
Source:
NCI/POG
Role:
Collaborator
Dates:
1988 - 2002
 
Title:
MRI assessment of Marrow Response to ALL Therapy, IN-18-31 ACS Institutional Award
Source:
ACS Institutional Award
Role:
Principal Investigator
Dates:
01/01/1989 - 12/31/1989
Direct Funds:
$7,500
 
Title:
MRI assessment of Marrow Response to ALL Therapy, IN-18-31
Source:
ACS Institutional Award
Role:
Principal Investigator
Dates:
1989 - Present
Direct Funds:
$7,200
 
Title:
The Use of Cyclosporin-A to Overcome Multiple Drug Resistance
Source:
Cancer Action
Role:
Principal Investigator
Dates:
07/01/1992 - 06/30/1994
Direct Funds:
$9,000
 
Title:
Clinical Investiation of MDR-1 and Late Effects in Childhood Cancer, CA06973
Source:
Cancer Center Support Grant (NIH CORE)
Role:
Principal Investigator
Dates:
05/01/1993 - 04/30/1996
Direct Funds:
$150,000 ($50,000/year)
 
Title:
The use of cyclosporine A to overcome multidrug resistance in osteosarcoma, POG9357
Source:
NIC/POG
Role:
Study Chairman
Dates:
1993 - 1997
 
Title:
Trial of ADR, CDDP and MTX with and without IFOS, with and without MTP-PE for Treatment of Osteogenic Sarcoma, POG9351
Source:
NCI POG
Role:
Study Chairman
Dates:
1993 - 1997
 
Title:
Pediatric Oncology Group U10 Award (Johns Hopkins), NIH NCI/2 U10 CA 28476
Source:
NIH/NCI
Role:
Principal Investigator
Dates:
04/15/1994 - 02/28/2002
Direct Funds:
$1,058,532
 
Title:
A Randomized, Double-Blind, Open Label, Trial of AmBisome Liposomal
Source:
Pfizer
Role:
Principal Investigator
Dates:
1994 - 1996
Direct Funds:
$131,000
 
Title:
Treatment of Children with Recurrent or Refractory Hodgkin's Disease, Wilms' Tumor, Ewing's Saroma, Rhabdomyosarcoma or Other Soft Tissue Sarcomas with Cyclosporine-A, Actinomycin-D, Vincristine - A Pediatric Oncology Group Phase II Study, POG 9227
Source:
NCI/POG
Role:
Study Chairman
Dates:
1995 - 1998
 
Title:
Phase I Study to Determine the Safety and Pharmacokinetics of FK463 in febrile neutropenic pediatric patients, 98-0-043 M680301-2068
Source:
Fujisawa
Role:
Principal Investigator
Dates:
1995 - 2001
Direct Funds:
$111,500
 
Title:
Etoposide/Ifosfamide + G-CSF in the Treatment of Newly Diagnosed Metastic Osteosarcoma or Unresectable Osteosarcoma. A Pediatric Oncology Group Phase II Study, P9450
Source:
NCI POG
Role:
Collaborator
PI:
A. Goorin
Dates:
1995 - 1999
 
Title:
Evaluation of Risk for Myocardial Ischemia in Survivors of Hodgkin's Disease Treated with Mediastinal Radiation, CA 0697335S1
Source:
NIH/NCI
Role:
Principal Investigator
Dates:
05/01/1997 - 04/30/1999
Direct Funds:
$292,870
 
Title:
Hopkins, Phase 1 POG Trial, M01RR000052
Source:
NIH/NCI
Role:
Principal Investigator
Dates:
12/01/1997 - 09/30/1999
Direct Funds:
$40,735
 
Title:
Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study. Dose dense, response based therapy using ABVE-PC, P9425
Source:
NCI/POG
Role:
Study Chairman
Dates:
1997 - 2001
 
Title:
Behavioral Medicine Approaches to Pediatric Acute Pain, 5ROL HD35528
Source:
Pediatric Oncology Group
Role:
Co-Investigator
PI:
Keith Slifer, PhD
Dates:
01/01/1998 - 03/31/2001
Direct Funds:
$24,188
 
Title:
A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients with Persistent Fever and Neutropenia, 97-N-0042
Source:
Pfizer
Role:
Principal Investigator
Dates:
1998 - 1999
 
Title:
Open, Intravenous Multiple Dose, Multi-Center Study to Investigate the Pharmocokinetics, Safety and Toleratipn of Voriconazone in Children Ages 2-12 years, A15010076045 M6813012127
Source:
Pfizer
Role:
Principal Investigator
Dates:
1998 - 2000
Direct Funds:
$5,182
 
Title:
Pediatric Oncology Group Phase I grant at Johns Hopkins, Agreement #0600-370-C352JHPX
Source:
NIH/NCI
Role:
Pricipal Investigator
Dates:
07/01/1999 - 06/30/2002
Direct Funds:
$40,000
 
Title:
Companion to Group-Wide Therapeutic Studies, POG 9851
Source:
POG/COG
Role:
Collaborator
PI:
R. Gorlick
Dates:
1999 - 2008
 
Title:
Osteosarcoma Biology Protocol: Companion to Group-Wide Therapeutic Studies, POG 9851
Source:
POG/COG
Role:
Collaborator
PI:
R. Gorlick
Dates:
1999 - 2008
 
Title:
Prospectively randomized double blind comparative multicenter study to evaluate efficacy and safety of Nyotran vs. amphotericin B for empiric antifungal treatment in neutropenic patints
Source:
Aronex
Role:
Principal Investigator
Dates:
1999 - 2000
 
Title:
Phase I Study to Determine the Safety and Pharmacokinetics of FK463 in febrile neutropenic pediatric patients, 98-0-043 M6813012105
Source:
Fujisawa
Role:
Principal Investigator
Dates:
1999 - 2001
Direct Funds:
$242,900
 
Title:
A Pilot Study. Intensified therapy for ifosfamide/etoposide or high cumulative dose doxorbicin with dexrazoxane, P9754
Source:
NCI/POG
Role:
Study Chairman
Dates:
1999 - 2002
 
Title:
Protocol for Patients with Newly-Diagnosed, Non-metastic Osteosarcoma: A Pilot Study. Intensified therapy for ifosfamide/etoposide or high cumulative dose doxorbicin with dexrazoxane, P9754
Source:
NCI/POG
Role:
Study Chairman
Dates:
1999 - 2002
 
Title:
Pediatrci Oncology Group, Hodgkin's Disease Committee Chair Funding, NIH NCI/2 U10 CA 288 76 17
Source:
NIH/NCI
Role:
Chair
Dates:
01/01/2000 - 12/31/2002
Direct Funds:
$27,285
 
Title:
Phase I/II Trial of Samarium in High-Risk Osteogenic Sarcoma
Source:
Berlix
Role:
Principal Investigator
Dates:
2000 - 2002
Direct Funds:
$73,582
 
Title:
Phase 1B Study of the Safety, Tolerance, Pharmacokinetics of Oral Posaconazole in Immunocompromised Children with Neutropenia, MK0991
Source:
Merck
Role:
Principal Investigator
Dates:
2000
Direct Funds:
$6,115
 
Title:
A Pilot Study of Re-Induction Chemotherapy with Ifosfamide, and Vinorelbine (IV) in Children with Refractory/Relapsed Hodgkin Disease, AHOD0091
Source:
NCI COG
Role:
HL Committee Chair and Study Committee Member
Dates:
2001 - 2006
 
Title:
Mk-0091 (Caspofungin) Pediatric PK Study, MK-0091
Source:
Merck
Role:
Principal Investigator
Dates:
2001 - 2002
 
Title:
SPORE in Lymphoma Project 1 EBV and Hodgkin's Disease, 1P50CA096888
Source:
NIH/NCI
Role:
Principal Investigator
PI:
Ambinder
Dates:
07/01/2002 - 06/30/2007
Direct Funds:
$13,279,453
 
Title:
Movement Restriction Fatigue in Cancer Survivors, RR000052-430965
Source:
NIH/NCI
Role:
Principal Investigator
Dates:
12/01/2002 - 11/30/2003
Direct Funds:
$149,500
 
Title:
Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD) 1/06-11/10. AHOD0031: A Phase III Study of Dose-Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease, AHOD03P1
Source:
NCI COG
Role:
Study Vice-Chair and Committee Chair
PI:
B. Appel
Dates:
2002 - 2009
 
Title:
A Phase III Study of Dose-Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease, AHOD03P1
Source:
NCI COG
Role:
Study Vice-Chair and Committee Chair
PI:
B. Appel
Dates:
2002 - 2009
 
Title:
Chair COG Hodgkin Lymphoma Chair and Principal Investigator U10CA098543
Source:
NIH/NCI
Role:
Chair and Principal Investigator
Dates:
01/01/2003 - 10/2013
Direct Funds:
$27,161,785
 
Title:
Neurobehavioral Outcome after CNS Prophylaxis without RT in ALL, NIH 5M01RR000052-430965
Source:
NIH
Role:
Principal Investigator
Dates:
12/01/2003 - 11/30/2004
Direct Funds:
$24,000
 
Title:
A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy with Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease, AHOD0121
Source:
NCI COG
Role:
Committee Chair and Study Committee member
PI:
A. Chen
Dates:
2003 - 2007
 
Title:
Health Outcomes for Hodgkin Disease Survivors
Source:
NIH/NCI
Role:
Co-Investigator and Study Vice-Chair
PI:
D. Friedman
Dates:
06/2004 - 06/2008
Direct Funds:
$1,551,968 ($45,463/year)
 
Title:
A Phase II Study of Weekly Gemcitabine and Vinorelbine in Children with Recurrent or Refractory Hodgkin Disease, AHOD0321
Source:
NCI COG
Role:
Committee Chair and Study Committee Investigator
PI:
P. Cole
Dates:
2004 - 2007
 
Title:
Health-Related Outcomes for Hodgkin Disease Survivors, ALTE04N!
Source:
NCI COG
Role:
Study Vice Chair
PI:
Friedman
Dates:
2004 - 2011
 
Title:
Phase I: Samarium-153 for recurrent or metastatic osteosarcoma
Source:
Cytogen
Role:
Principal Investigator
Dates:
2005 - 2006
 
Title:
Hodgkin Disease Banking Study, AHOD04B!
Source:
NCI COG
Role:
Committee Chair and Study Investigator
Dates:
2006 - Present
 
Title:
Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low-Risk Hodgkin Disease, AHOD 0431
Source:
NCI COG
Role:
Committee Chair and Study Investigator
PI:
F. Keller
Dates:
2006 - 2009
 
Title:
A Phase 1/Phase 2 Study of CP-751,871 in Patients with replapsed and/or Refractory Eqing's Sarcoma Family of Tumors, A4021020
Source:
Pfizer
Role:
Principal Investigator (Hopkins)
Dates:
2007 - Present
 
Title:
Dana Farber Cancer Institute - ALL Consortium
Role:
PI-RIH
PI:
Stephen Sallan
Dates:
2007 - 09/30/2013
 
Title:
Pediatric Oncology Infrastructure support
Source:
Cure Kids Cancer Radiothon
Role:
Principal Investigator
Dates:
2009 - 09/30/2013
Direct Funds:
$225,000 ($75,000/year)
 
Title:
Modeled Reduction in Late Effects (MORALE)
Source:
Canadian Institutes of Health Research
Role:
Co-Investigator
PI:
Hodgson
Dates:
03/01/2010 - 03/01/2011
Direct Funds:
$89,557
 
Title:
Telephone-based Counseling Intervention for Primary Caregivers, R21-141313
Source:
NIH/NCI
Role:
Co-Investigator, 2%
PI:
Debra Friedman, MD
Dates:
09/01/2011 - 09/30/2013
Direct Funds:
$417,423 ($6114/year)
 
Title:
Perspectives Regarding Fertility in Female Adolescent and Young Adult Childhood Cancer Survivors
Source:
Cure Kids Cancer Radiothon
Role:
Co-Investigator
PI:
P. Rao
Dates:
2011 - 2012
Direct Funds:
$6,000
 
Title:
Long term survivorship program
Source:
Hyundai Research Grant
Role:
Principal Investigator
Dates:
2011 - 2012
Direct Funds:
$100,000
 
Title:
Pilot: Regional Promotion of Healthy Behaviors in Adolescent Cancer Survivors
Source:
Cure Kids Cancer Radiothon
Role:
Principal Investigator
Dates:
2012 - 2013
Direct Funds:
$35,000
 
Title:
A Research Infrastructure for Adolescent Survivorship in New England
Source:
St. Baldrick's Foundation
Role:
Prncipal Investigator
Dates:
2012 - 2013
Direct Funds:
$49,729
 
Title:
The role of MGMT in Pediatric Hodgkin Lymphoma and Chemotherapy Induced Toxicities, AHOD13B2
Role:
Study Chairman
Dates:
2013 - 2014
 
Title:
A Randomized Phase III Study of Brentuximab vedotin (Bv) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL), AHOD1331
Source:
NCI COG
Role:
Principal Investigator
PI:
Schwartz
Dates:
2015 - Present
 
Title:
Modulating FAS expression to improve outcome for patients with refractory osteosarcoma
Source:
GAC
Role:
Co-Principal Investigator
PI:
Schwartz CL and Harrison D
Dates:
04/01/2016 - 03/31/2017
Direct Funds:
$50,000 ($50,000/year)
 
Title:
Phase I pen labe, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with neuroectodermal tumours, rhabdomyosarcoma and/or other solid, 00051236
Source:
Boehringer Ingelheim
Role:
Collaborator (MDACC)
PI:
D. Harrison
Dates:
2016
 
Title:
Longitudinal Biospecimen Acquisition for All Tumor Types for Adaptive Patient Oriented Longitudinal Learning and Optimization (APOLLO)
Role:
Collaborator
Dates:
2016
 
Title:
Study of the Safety and Pharmacokinetics of anti-PD-L1 antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors, 2015-00051260
Source:
Memorial Sloan-Ketterin Cancer Center
Role:
Collaborator (MDACC)
Dates:
2016 - Present
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Schwartz CL and Phelan R, Late Effects & Transition into Primary Care, Pediatric, Adolescent and Young Adult Survivorship Conference, Harley Davidson Museum, Milwaukee, WI, 10/2018
 
National
Conference Chair, Johns Hopkins University, Progress in Hematologic Malignancy, BMT and Pediatric, Baltimore, MD, 1995
Moderator, National Cancer Institute (NCI) Office of Cancer Survivorship, Bethesda, MD, 1998
Conference Chair, 1st Annual Conference, Johns Hopkins Hodgkin’s Cohort, Survival After Hodgkin's Disease, Baltimore, MD, 1999
Chair, American Society of Pediatric Hematology/Oncology (ASHPO), Bone Tumor Symposium, Minneapolis, MN, 2000
Conference Chair, 2nd Annual Conference, Johns Hopkins Hodgkin’s Cohort, Baltimore, MD, 2000
Chair, American Society of Pediatric Hematology/Oncology (ASHPO), Lymphoma Symposium, Baltimore, MD, 2002
Chair, American Society of Clinical Oncology (ASCO), Educational Session, Response Based Therapy: A Personalized Approach To Pediatric Hodgkin Lymphoma, Chicago, IL, 2010
Co-Chair, 2nd International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma, Frontline Therapy of Hodgkin Lymphoma, Arlington, VA, 2011
Discussant, American Society of Clinical Oncology (ASCO), What is the Way Forward in Osteosarcoma?, Chicago, IL, 2013
Discussant, American Society of Clinical Oncology (ASCO), Late Cardiopulmonary Complications of Cancer Therapy, Chicago, IL, 2014
 
International
Co-Chair, Clinical Trials in Pediatric Oncology, International Society of Paediatric Oncology (SIOP) and American Society of Pediatric Hematology/Oncology (ASHPO), Montreal, Canada, 1999
Co-Chair, International Workshop on Prognostic Factors in Pediatric Hodgkin Lymphoma, Paris, France, 2004
Chair, 8th International Symposium on Hodgkin Lymphoma, Workshop on Pediatric Hodgkin Lymphoma, Cologne, Germany, 2010
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Schwartz CL, Bender KS, Burke PJ, Kan JS, Civin CI. QT interval prolongation and cardiac dysrhythmia in a patient receiving amsacrine. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):1043-4.
2. Noga SJ, Donnenberg AD, Schwartz CL, Strauss LC, Civin CI, Santos GW. Development of a simplified counterflow centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow. Transplantation. 1986 Feb;41(2):220-9.
3. Noga SJ, Cremo CA, Duff SC, Schwartz CL, Melaragno A, Civin CI, Donnenberg AD. Large scale separation of human bone marrow by counterflow centrifugation elutriation. J Immunol Methods. 1986 Sep 27;92(2):211-8.
4. Noga SJ, Schwartz CL, Civin CI, Loken M, Donnenberg AD. Rapid separation of whole human bone marrow aspirates by counterflow centrifugation elutriation. Transplantation. 1987 Mar;43(3):438-40.
5. Schwartz CL, Minniti CP, Harwood P, Na S, Banquerigo ML, Strauss LC, Kurtzberg J, Smith SD, Civin CI. Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin. J Clin Oncol. 1987 Dec;5(12):1900-11.
6. Henrickson KJ, Powell KR, Schwartz CL. A dilute solution of vancomycin and heparin retains antibacterial and anticoagulant activities. J Infect Dis. 1988 Mar;157(3):600-1.
7. Schwartz CL, Miller NR, Wharam MD, Leventhal BG. The optic nerve as the site of initial relapse in childhood acute lymphoblastic leukemia. Cancer. 1989 Apr 15;63(8):1616-20.
8. Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol. 1990 Sep;8(9):1591-7.
9. Schwartz CL. Creating life on the plateau: reproductive potential in survivors of childhood Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):1099-100.
10. Wang N, Cedrone E, Dry J, Skuse GR, Schwartz C, Terryberry S. Transposition of the oncogene ets-1 in t(11;19) translocation in acute leukemia. Cancer Genet Cytogenet. 1990 Dec;50(2):199-205.
11. Tulikangas P, Hobbie W, Schwartz CL. Cyclophosphamide treatment for childhood leukemia: Effects on reproductive function. J Univ Rochester Med Center, 1991.
12. Schwartz CL, Hobbie WL, Truesdell S, Constine LC, Clark EB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol. 1993 Oct;11(10):1906-10.
13. Rosier RN, Teot LA, Hicks DG, Schwartz C, O'Keefe RJ, Puzas JE. Multiple drug resistance in osteosarcoma. Iowa Orthop J. 1995;15:66-73. PMCID: PMC2329065
14. Korones DN, Weidner S, Schwartz CL. Intermittent high-dose deferoxamine for patients with iron overload and sickle anemia. Int J Pediatr Hematol/Oncol(3):53-6, 1996.
15. O'Reilly R, Link M, Fletcher B, Gebhardt M, Krance R, Meyers P, Neff J, Schwartz C. NCCN pediatric osteosarcoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1799-806, 1812.
16. Dome JS, Schwartz CL. Osteosarcoma. Cancer Treat Res. 1997;92:215-51.
17. Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.
18. Walsh TJ, Finberg R, Arndt C, Hiemenz J, Schwartz CL, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. A Randomized, Double-Blind, Multicenter Trial of Liposomal Amphotericin B versus Conventional Amphotericin B for Empirical Antifungal Therapy of Persistently Febrile Neutropenic Patients. N Engl J Med(11):794-771, 1999.
19. Spunt SL, Lobe TE, Pappo AS, Parham DM, Wharam MD, Arndt C, Anderson JR, Crist WM, Paidas C, Wiener E, Andrassy RJ, Schwartz CL. Rhabdomyosarcoma of the Biliary Tract in Children and Adolescents - The Intergroup Rhabdomyosarcoma Study Group Experience (1972-98). J. Pediatr Surg(35):309-321, 2000.
20. Spunt SL, Lobe TE, Pappo AS, Parham DM, Wharam MD Jr, Arndt C, Anderson JR, Crist WM, Paidas C, Wiener E, Andrassy RJ, Schwartz CL. Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma. J Pediatr Surg. 2000 Feb;35(2):309-16.
21. Lipton JM, Federman N, Khabbaze Y, Schwartz CL, Hilliard LM, Clark JI, Vlachos A, Diamond-Black Anemia Registry. Osteogenic sarcoma associated with Diamond-Blackfan anemia: a report from the Diamond-Blackfan Anemia Registry. J Pediatr Hematol Oncol. 2001 Jan;23(1):39-44.
22. Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, Sallan SE. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001 Feb 15;19(4):1040-6.
23. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M, Grier HE. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002 Jan 15;20(2):426-33.
24. Meij P, Vervoort MB, Bloemena E, Schouten TE, Schwartz C, Grufferman S, Ambinder RF, Middeldorp JM. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. J Med Virol. 2002 Nov;68(3):370-7.
25. Welsh JS, Thurman SA, Borzillary S, Schwartz CL, Howard SP. Sm-153 EDTMP for recurrent metastatic osteosarcoma. Clin Adv Hematol Oncol. 2003 Mar;1(3):181-3; discussion 183.
26. Adams MJ, Lipshultz SE, Schwartz C, Fajardo LF, Coen V, Constine LS. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol. 2003 Jul;13(3):346-56.
27. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003 Nov 15;9(15):5442-53.
28. Schwartz CL. Health status of adult long-term survivors of childhood cancer:a report from the Childhood Cancer Survivor Study. J Pediatr. 2004 Mar;144(3):407-8.
29. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005 Mar 20;23(9):2004-11.
30. Schwartz CL. Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl. 2005 Jul(66):55-62.
31. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005 Aug;49(8):3317-24. PMCID: PMC1196271
32. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005 Nov;49(11):4536-45. PMCID: PMC1280172
33. Wimmer RS, Chauvenet AR, London WB, Villaluna D, de Alarcon PA, Schwartz CL. APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. Pediatr Blood Cancer. 2006 Mar;46(3):320-4.
34. Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, Wharam MD, Falletta JM, de Alarcon P, Chauvenet AR, Children's Oncology Group. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2006 Jun;28(6):362-8.
35. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006 Oct 12;355(15):1572-82.
36. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007 Feb 10;25(5):493-500.
37. Ehrlich PF, Friedman DL, Schwartz CL, Children Oncology Group Hodgkin Lymphoma study section. Monitoring diagnostic accuracy and complications. A report from the Children's Oncology Group Hodgkin lymphoma study. J Pediatr Surg. 2007 May;42(5):788-91.
38. Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P, Children's Oncology Group. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol. 2007 May 20;25(15):2057-62.
39. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ, ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007 Sep 01;25(25):3991-4008.
40. Mahone EM, Prahme MC, Ruble K, Mostofsky SH, Schwartz CL. Motor and perceptual timing deficits among survivors of childhood leukemia. J Pediatr Psychol. 2007 Sep;32(8):918-25.
41. Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007 Oct;51(10):3714-9. PMCID: PMC2043253
42. Terlou A, Ruble K, Stapert AF, Chang HC, Rowe PC, Schwartz CL. Orthostatic intolerance in survivors of childhood cancer. Eur J Cancer. 2007 Dec;43(18):2685-90.
43. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE, Children's Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008 Feb 01;26(4):633-8.
44. Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer. 2008 Mar;50(3):667-70.
45. Lucas KG, Schwartz C, Kaplan J. Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma. Pediatr Blood Cancer. 2008 Jul;51(1):142-4.
46. Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, Basu SK, Kun LE, Ng A, Mauch P, Sandhu A, Culakova E, Lyman G, Mendenhall N. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008 Sep 01;72(1):24-33. PMCID: PMC3531236
47. Basu SK, Schwartz C, Fisher SG, Hudson MM, Tarbell N, Muhs A, Marcus KJ, Mendenhall N, Mauch P, Kun LE, Constine LS. Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2008 Sep 01;72(1):34-40. PMCID: PMC3532026
48. Trask CL, Welch JJ, Manley P, Jelalian E, Schwartz CL. Parental needs for information related to neurocognitive late effects from pediatric cancer and its treatment. Pediatr Blood Cancer. 2009 Feb;52(2):273-9.
49. Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol. 2009 Mar 20;27(9):1456-61. PMCID: PMC2668553
50. Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009 Jun 01;115(11):2514-22. PMCID: PMC2974628
51. Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 03;114(10):2051-9. PMCID: PMC2744567
52. Kelly MJ, Vivier PM, Panken TM, Schwartz CL. Bacteremia in febrile nonneutropenic pediatric oncology patients. Pediatr Blood Cancer. 2010 Jan;54(1):83-7.
53. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18;115(7):1351-3. PMCID: PMC2826760
54. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O'Holleran EW, Neuberg DS, Cohen HJ, Sallan SE. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010 Feb;24(2):320-34. PMCID: PMC2820141
55. Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer. 2010 May-Jun;34(3):211-27.
56. Fitzgerald TJ, Bishop-Jodoin M, Cicchetti MG, Hanusik R, Kessel S, Laurie F, McCarten KM, Moni J, Pieters RS, Rosen N, Ulin K, Urie M, Chauvenet AR, Constine LS, Deye J, Vikram B, Friedman D, Marcus RB Jr, Mendenhall NP, Williams JL, Purdy J, Saltz J, Schwartz CL, White KS, Wolden S. Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: in regard to Bekelman and Yahalom (Int J Radiat Oncol Biol Phys 2009;73:492-498). Int J Radiat Oncol Biol Phys. 2010 May 01;77(1):315-6. PMCID: PMC2908913
57. Cole PD, McCarten KM, Drachtman RA, Alarcon Pd, Chen L, Trippett TM, Schwartz CL. Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report. Pediatr Hematol Oncol. 2010 Nov;27(8):650-7. PMCID: PMC3083978
58. Loeb DM, Hobbs RF, Okoli A, Chen AR, Cho S, Srinivasan S, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer. 2010 Dec 01;116(23):5470-8. PMCID: PMC2991401
59. Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II. J Am Coll Radiol. 2011 May;8(5):302-8.
60. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdière C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, Sallan SE. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun;47(9):1373-9. PMCID: PMC3736806
61. Kenney LB, Bradeen H, Kadan-Lottick NS, Diller L, Homans A, Schwartz CL. The current status of follow-up services for childhood cancer survivors, are we meeting goals and expectations: a report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2011 Dec 01;57(6):1062-6.
62. Voss SD, Chen L, Constine LS, Chauvenet A, Fitzgerald TJ, Kaste SC, Slovis T, Schwartz CL. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2635-40. PMCID: PMC4559601
63. Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer. 2012 Sep 15;118(18):4597-605. PMCID: PMC4008337
64. Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. PMCID: PMC3468662
65. Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, Hoppe BS, Ng A, Roberts KB, Shapiro R, Wilder RB, Yunes MJ, Constine LS. ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma. Pediatr Blood Cancer. 2014 Jul;61(7):1305-12.
66. Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014 Nov 10;32(32):3651-8. PMCID: PMC4220044
67. Gorlick S, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gill J, Geller D, Randall RL, Janeway K, Schwartz C, Grier H, Meyers PA, Gorlick R, Bernstein M, Marina N. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatr Blood Cancer. 2014 Sep;61(9):1558-64. PMCID: PMC4288578
68. Trippett TM, Schwartz CL, Guillerman RP, Gamis AS, Gardner S, Hogan S, London WB, Chen L, de Alarcon P. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatr Blood Cancer. 2015 Jan;62(1):60-4. PMCID: PMC4465390
69. Harrison DJ, Schwartz C. Survivorship. J Surg Oncol. 2015 Apr;111(5):648-55.
70. Dharmarajan KV, Friedman DL, FitzGerald TJ, McCarten KM, Constine LS, Chen L, Kessel SK, Iandoli M, Laurie F, Schwartz CL, Wolden SL. Radiotherapy quality assurance report from children's oncology group AHOD0031. Int J Radiat Oncol Biol Phys. 2015 Apr 01;91(5):1065-71. PMCID: PMC5240783
71. Dharmarajan KV, Friedman DL, Schwartz CL, Chen L, FitzGerald TJ, McCarten KM, Kessel SK, Iandoli M, Constine LS, Wolden SL. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2015 May 01;92(1):60-6. PMCID: PMC4395527
72. Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, Guillerman RP, Buxton A, Howard SC, Hogan SM, Sheehan AM, López-Terrada D, Mrazek MD, Agrawal N, Wu MF, Liu H, De Alarcon PA, Trippet TM, Schwartz CL. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol. 2015 Jul;170(1):118-22. PMCID: PMC4478135
73. Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, Armenian SH. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. J Clin Oncol. 2015 Aug 20;33(24):2639-45. PMCID: PMC4534526
74. Macpherson CF, Hooke MC, Friedman DL, Campbell K, Withycombe J, Schwartz CL, Kelly K, Meza J. Exercise and Fatigue in Adolescent and Young Adult Survivors of Hodgkin Lymphoma: A Report from the Children's Oncology Group. J Adolesc Young Adult Oncol. 2015 Sep;4(3):137-40. PMCID: PMC4575513
75. Keller FG, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM, Senn SL, Buxton A, Constine LS, Schwartz CL. Results of the AHOD0431 Trial of Response Adapted Therapy and a Salvage Strategy for Limited-Stage Classical Hodgkin Lymphoma: A Report from the Children’s Oncology Group, J Clin Oncol, Resubmitted, 2016.
76. Schwartz CL, Wexler LH, Krailo MD, Teot LA, Devidas M, Steinherz LJ, Goorin AM, Gebhardt MC, Healey JH, Sato JK, Meyers PA, Grier HE, Bernstein ML, Lipshultz SE. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2016 Jan;63(1):54-61. PMCID: PMC4779061
77. Appel BE, Chen L, Buxton AB, Hutchison RE, Hodgson DC, Ehrlich PF, Constine LS, Schwartz CL. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group. J Clin Oncol. 2016 07 10;34(20):2372-9. PMCID: PMC4981978
78. Bishop MW, Chang YC, Krailo MD, Meyers PA, Provisor AJ, Schwartz CL, Marina NM, Teot LA, Gebhardt MC, Gorlick R, Janeway KA, Chou AJ. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2016 10;63(10):1737-43. PMCID: PMC5136499
79. Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396-1408. PMCID: PMC5052459
80. Charpentier AM, Friedman DL, Wolden S, Schwartz C, Gill B, Sykes J, Albert-Green A, Kelly KM, Constine LS, Hodgson DC. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial. Int J Radiat Oncol Biol Phys. 2016 12 01;96(5):943-950. PMCID: PMC5584603
81. Welch JGJ, Schwartz CL, Higman M, Chen L, Buxton A, Kanakry JA, Kahwash SB, Hutchison RE, Friedman DL, Ambinder RF. Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Advances, In Press, 2017.
82. Kaul S, Avila JC, Mutambudzi M, Russell H, Kirchhoff AC, Schwartz CL. Mental distress and health care use among survivors of adolescent and young adult cancer: A cross-sectional analysis of the National Health Interview Survey. Cancer. 2017 03 01;123(5):869-878.
83. Schwartz CL, Chen L, McCarten K, Wolden S, Constine LS, Hutchison RE, de Alarcon PA, Keller FG, Kelly KM, Trippet TA, Voss SD, Friedman DL. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 04;64(4). PMCID: PMC5702912
84. Esbenshade AJ, Zhao Z, Aftandilian C, Saab R, Wattier RL, Beauchemin M, Miller TP, Wilkes JJ, Kelly MJ, Fernbach A, Jeng M, Schwartz CL, Dvorak CC, Shyr Y, Moons KGM, Sulis ML, Friedman DL. Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer. 2017 Oct 01;123(19):3781-3790. PMCID: PMC5610619
85. Fernández KS, Schwartz CL, Chen L, Constine LS, Chauvenet A, de Alarcón PA. Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report. Pediatr Blood Cancer. 2017 Dec;64(12). PMCID: PMC5799083
86. Esbenshade AJ, Zhao Z, Aftandilian C, Saab R, Wattier RL, Beauchemin M, Miller TP, Wilkes JJ, Kelly MJ, Fernbach A, Jeng M, Schwartz CL, Dvorak CC, Shyr Y, Moons KGM, Sulis ML, Friedman DL. Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer. 2017 Oct 01;123(19):3781-3790. PMCID: PMC5610619
87. Fernández KS, Schwartz CL, Chen L, Constine LS, Chauvenet A, de Alarcón PA. Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report. Pediatr Blood Cancer. 2017 Dec;64(12). PMCID: PMC5799083
88. Aldrink JH, Appel B, Kaplan JA, Hutchison RE, Schwartz CL, Kelly KM, McCarten K, Ehrlich PF. Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. J Pediatr Hematol Oncol. 2018 04;40(3):246-247. PMCID: PMC5866194
89. Welch JJG, Schwartz CL, Higman M, Chen L, Buxton A, Kanakry JA, Kahwash SB, Hutchison RE, Friedman DL, Ambinder RF. Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Adv. 2017 Apr 25;1(11):681-684. PMCID: PMC5727814
90. Keller FG, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM, Senn SL, Buxton AB, Bush R, Constine LS, Schwartz CL. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group. Cancer. 2018 08 01;124(15):3210-3219. PMCID: PMC6097921
91. Parzuchowski A, Bush R, Pei Q, Friedman DL, FitzGerald TJ, Wolden SL, Dharmarajan KV, Constine LS, Laurie F, Kessel SK, Appel B, Fernandez K, Punnett A, Schwartz CL, Cox J, Terezakis SA. Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031. Int J Radiat Oncol Biol Phys. 2018 04 01;100(5):1119-1125. PMCID: PMC6555555
92. McCarten KM, Metzger ML, Drachtman RA, Pei Q, Friedman DL, Schwartz CL, Kelly KM. Significance of pleural effusion at diagnosis in pediatric Hodgkin lymphoma: a report from Children's Oncology Group protocol AHOD0031. Pediatr Radiol. 2018 11;48(12):1736-1744. PMCID: PMC6208959
93. Marks LJ, McCarten KM, Pei Q, Friedman DL, Schwartz CL, Kelly KM. Pericardial effusion in Hodgkin lymphoma: a report from the Children's Oncology Group AHOD0031 protocol. Blood. 2018 09 13;132(11):1208-1211. PMCID: PMC6137557
94. Welch JJG, Kenney LB, Hirway P, Usmani GN, Kadan-Lottick N, Grewal SS, Huang M, Bradeen H, Ader J, Diller L, Schwartz CL. Understanding predictors of continued long-term pediatric cancer care across the region: A report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2017 Oct;64(10).
95. Harrison DJ, Schwartz CL. Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease. Curr Treat Options Oncol. 2017 04;18(4):24.
96. Mauz-Körholz C, Metzger ML, Kelly KM, Schwartz CL, Castellanos ME, Dieckmann K, Kluge R, Körholz D. Pediatric Hodgkin Lymphoma. J Clin Oncol. 2015 Sep 20;33(27):2975-85.
97. Borinstein SC, Barkauskas DA, Bernstein M, Goorin A, Gorlick R, Krailo M, Schwartz CL, Wexler LH, Toretsky JA. Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer. 2014 Apr;61(4):749-52. PMCID: PMC3946315
98. Schwartz CL. Prognostic factors in pediatric Hodgkin disease. Curr Oncol Rep. 2003 Nov;5(6):498-504.
99. Schwartz CL. The management of Hodgkin disease in the young child. Curr Opin Pediatr. 2003 Feb;15(1):10-6.
100. Schwartz CL. Long-term survivors of childhood cancer: the late effects of therapy. Oncologist. 1999;4(1):45-54.
101. Schwartz CL. Late effects of treatment in long-term survivors of cancer. Cancer Treat Rev. 1995 Jul;21(4):355-66.
102. Hobbie WL, Schwartz CL. Endocrine late effects among survivors of cancer. Semin Oncol Nurs. 1989 Feb;5(1):14-21.
103. Schwartz CL, Cohen HJ. Preleukemic syndromes and other syndromes predisposing to leukemia. Pediatr Clin North Am. 1988 Aug;35(4):853-71.
104. Schwartz CL, Henrickson KJ, Roghmann K, Powell K.. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheter with vancomycin susceptible organisms. J Clin Oncol. (8):1591-1597.
105. Untanu RV, Back J, Appel B, Pei Q, Chen L, Buxton A, Hodgson DC, Ehrlich PF, Constine LS, Schwartz CL, Hutchison RE. Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 Jan;65(1). PMCID: PMC5699946
106. Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer. 2018 01 01;124(1):136-144. PMCID: PMC5735034
107. Schwartz CL. Creating life on the plateau: Reproductive potential in survivors of childhood Hodgkin's disease Int J Rad Onc Biol Phys. (19):1099-1100.
108. Spraker-Perlman HL, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Doski J, Gorlick R, Janeway KA, Isakoff MS. Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 01;66(1):e27444. PMCID: PMC6249072
109. Marks LJ, Pei Q, Bush R, Buxton A, Appel B, Kelly KM, Schwartz CL, Friedman DL. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 12;65(12):e27375. PMCID: PMC6192844
110. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019 Mar;109:36-50. PMCID: PMC6506906
111. Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY,Schwartz C. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol. 2019 Jun, [Epub ahead of print]
112. Lisa Kopp; Richard B. Womer, MD; Cindy L. Schwartz, MD, MPH; David H. Ebb, MD; Vivian I. Franco, MS; David Hall, MS; Donald A. Barkauskas, PhD; Mark D. Krailo, PhD; Holcombe E. Grier, MD; Paul A. Meyers, MD; Leonard H. Wexler, MD; Neyssa M. Marina, MD, MS; Katherine A. Janeway, MD; Richard Gorlick, MD; Mark L. Bernstein, MD; Steven E. Lipshultz, MD. Effects of Dexrazoxane on Doxorubicin-Related Cardiotoxicity and Second Malignant Neoplasms in Children with Osteosarcoma: A Report from the Children’s Oncology Group* Cardio-Oncology, In Press 2019
113. Kahn JM, Kelly KM, Pei Q, Bush R, Friedman DL, Keller FG, Bhatia S, Henderson TO, Schwartz CL, Castellino SM. Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study. J Clin Oncol. 2019 Nov 10;37(32):3009-3017. PMCID: PMC6839907
114. Schwartz CL. Creating a bridge for transition: From pediatric cancer survival to life-long, risk-based health care of the adult cancer survivor. Cancer. 2019 Oct 18.
115. Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol. 2019 Oct;187(1):39-48. PMCID: PMC6857800
116. Hall GW, Schwartz CL, Daw S, Constine LS. Pediatric hodgkin lymphoma Hematologic Malignancies. 1 December 2015;6:253-270.
117. Schwartz CL, Hobbie WL, Constine LS. Algorithms of late effects by disease Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:1-13.
118. Schwartz CL, Hobbie WL, Constine LS. Facilitating assessment of late effects by organ system Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:15-32.
119. Dhakal S, Weiner D, Schwartz C, Constine LS. Pulmonary effects of antineoplastic therapy Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:201-227.
120. Milano MT, Dhakal S, Schwartz CL, Constine LS. The thyroid gland Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:151-166.
121. Schwartz CL, Hobbie WL, Constine LS, Ruccione KS. Survivors of childhood and adolescent cancer: A multidisciplinary approach: Third Edition Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:1-436.
122. Schwartz CL, Hobbie WL, Constine LS. Facilitating assessment of late effects by organ system Pediatric Oncology. 2015;2015:15-32.
 
Books, Chapters, and Reviews
1. Schwartz CL, Cohen HJ. Myeloproliferative and myelodysplastic syndromes. In: Principles and Practice of Pediatric Oncology. Ed(s) Pizzo PA, Poplack DG. JB Lippincott Company: Philadelphia, PA, 397-413, 1989.
2. Schwartz CL. Myelodysplastic and myeloproliferative disorders in children. In: Hematology: Basic Principles and Practice. Ed(s) Hoffman R, Benz EJ, Shattil S, Furie B, Cohen HJ. Churchill Livingstone: New York, 889-896, 1991.
3. Schwartz CL. Cancers in Childhood. In: Pediatric Primary Care. Ed(s) Hoekelman R. Mosby: St. Louis, MO, 1157-1179, 1992.
4. Schwartz, CL. Retinoblastoma. In: Merck Manual, 16th Edition. Ed(s) Berkow R. Merck, Sharp & Dohme Research Laboratories: Rahway, New Jersey, 2205-2206, 1992.
5. Schwartz CL, Cohen HJ. Myeloproliferative and myelodysplastic syndromes. In: Principles and Practice of Pediatric Oncology, 2n edition. Ed(s) Pizzo PA, Poplack DG. JB Lippincott Company: Philadelphia, PA, 519-535, 1993.
6. Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Survivors of Childhood Cancer - Assessment and Management. Mosby Yearbook, Inc: Missouri, 1994.
7. Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Algorithms of Late Effects by Disease. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook: Missouri, 7-20, 1994.
8. Truesdell S, Schwartz CL, Clark E. Cardiovascular Effects of Therapy. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc.: Missouri, 159-176, 1994.
9. Constine LS, Hobbie WL, Schwartz CL. Facilitated Assessment of Chronic Treatment Effects by Symptom and Organ Systems. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc.: Missouri, 21-80, 1994.
10. Constine LS, Hobbie WL, Schwartz CL. Facilitated Assessment of Chronic Treatment Effects by Symptom and Organ Systems. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc.: Missouri, 7-20, 1994.
11. McDonald S, Rubin P, Schwartz CL. Pulmonary Effects of Antineoplastic Therapy. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc.: Missouri, 177-196, 1994.
12. Schwartz CL, Hobbie WL, Ruccione K, Constine LS. The Establishment of the follow-up Clinic. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Ruccione K, Constine LS. Mosby Yearbook, Inc.: Missouri, 367-389, 1994.
13. Constine LS, Schwartz CL. The Thyroid Gland. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc: Missouri, 151-158, 1994.
14. Schwartz, CL. Myelodysplastic and myeloproliferative disorders in children. In: Hematology: Basic Principles and Practice, 2nd edition. Ed(s) Benz EJ, Cohen HJ, Furie B, Hoffman R, Sharril S. Churchill Livingstone: New York, 1184-1192, 1995.
15. Schwartz CL. Cancers in Childhood. In: Pediatric Primary Care, 3rd Edition. Ed(s) Hoekelman R. Mosby Yearbook, Inc: Missouri, 1217-1238, 1997.
16. Korones DN, Schwartz CL. Myeloproliferative and myelodysplastic syndromes. In: Principles and Practice of Pediatric Oncology, 3rd Edition. Ed(s) Oldham KT, Colombani PM, Foglia RP. Lippincott-Raven: Philadelphia, 537-48, 1997.
17. Schwartz CL, Cohen HJ. Myeloproliferative and myelodysplastic syndromes. In: Principles and Practice of Pediatric Oncology, 3rd Edition. Ed(s) PA Pizzo, Poplack DG. JB Lippincott Company: Philadelphia, 505-521, 1997.
18. Korones DN, Schwartz CL. Principles of Oncology. In: Surgery of Infants and Children. Ed(s) Oldham KT, Colombani PM, Foglia RP. Lippincott-Raven: Philadelphia, 537-48, 1997.
19. Chauvenet, A, Schwartz CL, Weiner M. Hodgkin’s Disease in Children and Adolescents. In: Cancer Medicine, 5th Edition. Ed(s) Holland, Frei. B.C. Decker Inc, 2140-2150, 2000.
20. Schwartz, CL. Myelodysplastic and myeloproliferative disorders in children. In: Hematology: Basic Principles and Practice. Ed(s) Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P. Churchill Livingstone: New York, 1205-1212, 2000.
21. Constine LC, Paidas C, Schwartz CL, Korones DN. Pediatric solid tumors. In: Clinical Oncology, A Multidisciplinary Approach, 8th Edition. Ed(s) Rubin P. WB Saunders, 336-404, 2001.
22. Ruble K, Schwartz C. Sports for the Child with Cancer. In: ” Educating the Child with Cancer: A Guide for Parents & Teachers, Nancy Keen. Candlelighters Childhood Cancer Foundation, 2003.
23. Loeb D, Castleberry R, Schwartz CL. Myelodysplastic and myeloproliferative disorders in children. In: Hematology: Basic Principles and Practice. Ed(s) Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McFlave P. Churchill Livingstone: New York, 1297-1306, 2004.
24. Simpson L, Baird K, Korones DN, Schwartz CL. Principles of Oncology. In: Surgery of Infants and Children. Ed(s) Foglia RP. Lippincott-Raven: Philadelphia, 2004.
25. Schwartz CL, Hobbie, WL, Constine, L. Algorithms of Late Effects by Disease. In: Survivors of Childhood and Adolescent Cancer – A Multidisciplinary Approach. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Springer-Verlag & Co, 5-16, 2005.
26. Schwartz CL, Hobbie, WL, Constine, L. Facilitating Assessment of Late Effects by Organ System. In: Survivors of Childhood and Adolescent Cancer – A Multidisciplinary Approach. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Springer-Verlag & Co, 17-34, 2005.
27. Biswas T, Constine LS, Schwartz CL. The Thyroid Gland. In: Survivors of Childhood and Adolescent Cancer – A Multidisciplinary Approach. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Springer-Verlag & Co: Heidelberg, Germany, 125-132, 2005.
28. Hudson MM, Schwartz C, Constine LS. Treatment of Pediatric Hodgkin Lymphoma. In: Pediatric Lymphomas. Ed(s) Weinstein HJ, Hudson MM, Link MP. Springer: Heudekberg, Germany, 35-66, 2007.
29. Hinkle AS, Schwartz CL. Cancers in Childhood. In: Textbook of Pediatric Care. Ed(s) McInerny TK. American Academy of Pediatrics: Elk Grove Village, IL, 1873-1902, 2009
30. Schwartz CL. Early Response-based Therapy for Children with Hodgkin Lymphoma: A Surrogate for Using Biology to Effect Cure and Minimize Toxicity. In: ASCO Educational Book, 2010.
31. Ruble K, Schwartz C. Physical Activity. In: Educating the Child with Cancer: A Guide for Parents & Teachers. Ed(s) Keen N. American Childhood Cancer Organization, 2011.
32. Schwartz CL. Hodgkin Lymphoma (Commentary). In: Evidence Based Pediatric Oncology, 3rd Edition. Ed(s) Pinkerton R, Shankar A, Matthay KK. Wiley-Blackwell, 105-108, 2013.
33. Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Survivors of Childhood and Adolescent Cancer – A Multidisciplinary Approach, 3rd Edition. Springer-Verlag & Co: Heidelberg. In Press.
 
Editorials, Letters to Editor, Other
1. Schwartz CL. Health status of childhood cancer survivors: cure is more than the eradication of cancer. JAMA. 2003 Sep 24;290(12):1641-3.
2. Schwartz CL. Health status of adult long-term survivors of childhood cancer:a report from the Childhood Cancer Survivor Study. J Pediatr. 2004 Mar;144(3):407-8.
3. Schwartz, CL. “Creating a bridge for transition: From pediatric cancer survival to life-long risk-based health care of the adult cancer survivor" (CNCR-19-2267.R1) has been accepted for publication in Cancer. 2019
 
Abstracts
1. Schwartz CL, Friedman DL, McCarten K, Wolden S L, Voss S, Constine LS. Chen L. Early PET and CT as predictors of outcome in pediatric Hodgkin lymphoma, Society International Pediatric Oncology. Pediatric Blood Cancer 57(5):75, 2011.
2. Castellino C, keller F, Dunphy C, Nachman J, Constine L, Chen L, Schwartz C. Mixed Cellularity Histology Confers Favorable Prognosis in Children and Adolescents with Low Risk Hodgkin Lymphoma (HL). 1st International Symposium on Childhood, Asolescent, and Young Adulty Hodgkin Lymphona, 2011
3. Schwartz CL, Friedman DL, McCarten K, Wolden SL, Voss S, Constine LS, Chen L. Predictors of Early Response and Event Free Survival in Hodgkin Lymphoma (HL): PET vs CT Imaging. Proceedings ASCO, 2011
4. Fernandez KS, Chen L, Schwartz C, Chauvenet A, deAlarcon PA. Survival in Adolescents and Young Adults with Hodgkin Lymphoma Treated with Response-Based Chemotherapy on P9425 and P9426 Protocols: A Report From the Children’s Oncology Group. Blood 118:91, 2011.
5. Schwartz C, Chen L, Constine L, Wolden S, Keller FG, Kelly KM, Friedman DL. The Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma. Blood 118:3649, 2011.
6. Appel B, Chen L, Hutchison RE, Hodgson DC, Ehrlich P, Constine LC, Schwartz CL. 18F-FDG (FDG) OET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL). ASH, 2012.
7. Schwartz CL, Kaplan J, Chen L, Hutchison R, Friedman D. Albumin: A Predictor of EFS in MC Hodgkin Lymphoma. SIOP, 2012
8. Gorlick R, Barkauskas D, Krailo M, Piperdi S, Sowers R, Gorlick S, Gill J, Geller D, Randall L, Janeway K, Schwartz C, Grier H, Meyers P, Bernstein M, Marina N. HER2 Expression is Not Prognostic in Osteosarcoma. CTOS, 2012.
9. Kopp L, Bernstein ML, Schwartz CL, Ebb D, Krailo MD, Frier HE, Meyers PA,k Wexler LH, Marina N, Womer R, Janeway KA, Gorlick RG, Lipshultz SE. The Effects of Dexrazoxane on Cardiac Funtion and Secondary Malignant Neoplasms in Patients with Osteosarcoma (OS). Proceedings ASCO, 2012.
10. Appel B, Ehrlich P, Chen L, Hutchison RE, Hodgson DC, Constine LS, Schwartz CL. Treatment of Pediatric Stage IA Lympocyte-Predominant Hodgkin Lympoma with Surgical Resection Alone: A COG Report. Proceedings ASCO, 2012
11. Schwartz CL, Hirway P, Ader J, Bradeen HA, Grewal SS, Huang MS, Kadan-Lottick N, Usmani N, Kenney LB. Barriers to Survivorship Care - CONNECCS. Proceedings ASCO, 2013.
12. Appel B, Chen L, Hutchison RE, Hodgson DC, Ehrlich P, Constine LC, Schwartz CL. Treatment of pediatric lymphocyte predominant Hodgkin lymphoma (LPHL): A report from the Children's Oncology Group,. Proceedings ASCO, 2013.
13. Charpentier A, Friedman D, Wolden S, Schwartz C, Gill B, Sykes J, Albert-Green A, constine L, Kelly K, Hodgson D. Predictive Factor Analysis of Response-adapted Treatment for Chemotherapy-sensitive Pediatric Hodgkin Lymphoma: a Report from Children's Oncology Group Trial AHOD003. , 2014.
14. SM Castellino, F Keller, SVoss, S Cho, L Constine, JT homson, C Dunphy, K McCarten L Chen, and CLSchwartz. Outcomes and Patterns of Failure in Children/Adolescents with Low Risk Hodgkin Lymphoma (HL) Who are FDG-PET (PET3) Positive After AVPC Therapy. ISCAYAHL, 5/2015.
15. Subbiah V, Anderson P, W. Huh, Hess K, Ravi V, FernandezJG, Lui A, Daw N, Somaiah N, Kappadath C, Ravissini G, Ludwig J, ChawlaS, Benjamin RS, Patel S, Schwartz CL, Hong DS, Rohren E. Safety, Tolerability, and Feasibility of Alpha Particle Radium-223 Dichloride (223RaCI2) in High Risk Osteosarcoma: Phase I Dose Escalation Trial. Connective Tissue Oncology Society, 10/2015.
16. Moonat HR, Wang WL, Kenneth R. Hess, Schwartz CL, Moise M, Patel S, Benjamin RS, Lewis VO, Lazar A, Daw NC. Small Cell Osteosarcoma: The MD Anderson Cancer Center Experience. Connective Tissue Oncology Society, 10/2015.
17. Spaker-Perlman HL, Barkauskas DA, Meyers PA; Schwartz CL, Ebb DH, Doski JJ, Krailo MD, Gorlick R, Janeway KA. Survivial After Recurrence in Osteosarcoma: A Report from the Chidlren's Oncology Group. Connective Tissue Oncology Society, 10/2015.
18. Appel B, Chen L, Hutchison RE, Hodgson DC, Ehrlich P, Constine LC, Schwartz CL. 18F-FDG (FDG) PET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL), A Preliminary Retrospective Analysis of Children’s Oncology Group (COG) AHOD0031. Blood (ASH poster) Supplement, 2015.
19. Henderson TO, Parson SK, Wroblewski K, Chen L, Hong F, Smith SM, McNeer J, Advani R, Gascoyne RD, Constine L, Horning SJ, Bartlett NL, MD, Shah BD, MD, Connors JM, Leonard JP, Kahl BS, Kelly KM, Schwartz CL, Friedman DL,Gordon Li, Evens AM. Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treat on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031). Blood (ASH poster) Supplement, 2015.
20. Kelly KM, MD, Cole PD, Chen L, Robrets KB, Hodgson DC, McCarten K, Steve Y Cho SY, Schwartz C. Phase III Study of Response Adapted Therapy for the Treatment of children with Newly Diagnosed Very HIgh Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group. Blood, 2015.
21. Mottok A, Johnston RL, Chan FC, Scott DW, Friedman DL, Schwartz CL, Kelly K, Terzah M. Horton TM.Steidl C. Prediction of Primary Treatment Outcome Using Gene Expression Profiling of Pre-Treatment Biopsies Obtained from CHhildhood and Adolescent Hodgkin Lympjoma Patients. Blood Supplement(126), 12/2015
22. Shaw A, Schadler K, Schwartz CL, Kleinerman E. Exercise Preconditioning Mitigates Doxorubicin Uptake in Cardiac Tissue. Pediatric Blood and Cancer 63(S1):S66 (#4010), 5/2016.
23. Lewis B, Kresta K, Shaw A, Robert R, Maetzold B, Valderrama R, Harman N, Cion I, Franklin Q Morse E, Skillman D, Schwartz CL, Tewari P. Totally Excited about Moving, Mobility and Exercise: a Multidisciplinary Effort to Help Increase Mobility for Children, Adolescents and Young Adults During their Inpatient Admission. Pediatric Blood and Cancer 63(S1):S9, 5/2016.
24. Chow EF, Doody DR, Armenian SH, Aggarwal S, Baker KS, Bhatia S, Blythe NA, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Sasake N, Vrooman LM, Asselin BL, Schwartz CL, Lipshultz SE. Effect of Dexrazoxane on Heart Function Among LongTerm Leukemia and Lymphoma: A Report from the Children's Oncology Group (COG). ASH oral presentation 2016. In Press.
25. Giulino-Roth L, Pei Q, Buxton A, Wolden S, Constine LS, Kelly K, Schwartz CL, Friedman DL. Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report From The Children's Oncology Group Study AHOD0031. ASH poster 2016. In Press.
26. Moonat HR, Roxas M, Huh WW, Herzog CE, Piha-Paul S, Daw NC, Rytting M, Mote E, Ward EN, Amin Y, Meric-Bernstam F, Schwartz CL, Subbiah V. Phase I evaluation of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in children, adolescents and young adults with advanced solid tumors. Cancer Research 76(5 Supplement) (#A48), 3/2016.
27. Mottok A, Johnston RL, Chan FC, Scott DW, Friedman DL, Schwartz CL, Kelly KM, Horton TM.Steidl C. Prediction of primary treatment response and outcome using digital gene expression. 10th International Symposium of Hodgkin Lymphoma, Cologne, Germany. October 2016.
28. Kelly KM, Cole PD, Chen L, Roberts KB, Hodgson DC, McCarten K, Cho S, Schwartz CL. Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group. 10th International Symposium of Hodgkin Lymphoma, Cologne, Germany. October 2016.
29. Schwartz CL, Wolden S, Constine LC, Chen L, Friedman DL. CHIPS as a predictor of outcome in radiated vs. unradiated HL. 10th International Symposium of Hodgkin Lymphoma, Cologne, Germany. October 2016.
30. Kopp LM, Bernstein ML, Schwartz CL, et. al. Complete Dexrazoxane Cardioprotection for Cardiac Function but Incomplete Female Cardioprotection for Cardiac Structure in Doxorubicin-treated Osteosarcoma Survivors: Hearts Too Small for The Body. ASCO, submitted 2017.
31. Schwartz CL, Constine LC, Putnam TC, Cohen HJ. Pediatric solid tumors. In: Clinical Oncology, A Multidisciplinary Approach, 7th edition. Ed(s) Saunders WB, 251-298, 1993.
32. Schwartz CL, Truesdell SA, Clark EB. The Use of the QTc in screening for anthracycline related cardiotoxicity. In: Cardiac toxicity cardiomyopathy after Cancer Therapy. Ed(s) Bricker GT, D'Angio GJ, Green DM. John Wiley and Sons: New York, 103-108, 1993.
 

jenkins-FCD Prod-410 e9586552fe7f53c71f7923aa6e27aeabbd3c2473